Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
- Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model
- Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase inhibitors for disease modification
Lausanne, SWITZERLAND and San Francisco, CA, USA, 1 April 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces the publication of peer-reviewed data in the journal ACS Chemical Neuroscience regarding ASN90, an O GlcNAcase (OGA) inhibitor, and one of its leading candidates in clinical development for treating neurodegenerative proteinopathies.
